Agios Pharmaceuticals (AGIO) Other Non-Current Liabilities (2012 - 2026)

Agios Pharmaceuticals' Other Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $90000.0 for Q1 2026.

• Quarterly Other Non-Current Liabilities fell 89.77% year-over-year to $90000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $90000.0 (down 89.77% YoY) and the FY2025 annual result came in at $90000.0, down 89.77% from the prior year.
• Other Non-Current Liabilities was $90000.0 for Q1 2026 at Agios Pharmaceuticals, roughly flat from $90000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $3.3 million in Q4 2022 and bottomed at $90000.0 in Q3 2025.
• A 5-year average of $985562.5 and a median of $1.1 million in 2022 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities rose 9.57% — and 2025, when it sank 92.21%.
• Agios Pharmaceuticals' Other Non-Current Liabilities stood at $3.3 million in 2022, then tumbled by 64.75% to $1.2 million in 2023, then declined by 23.88% to $880000.0 in 2024, then slumped by 89.77% to $90000.0 in 2025, then changed by 0.0% to $90000.0 in 2026.
• Business Quant data shows AGIO's Other Non-Current Liabilities at $90000.0 in Q1 2026, $90000.0 in Q4 2025, and $90000.0 in Q3 2025.